




















Exploring the Diagnostic Journeys of Women with Systemic Lupus Erythematosus in New 
York City: A Qualitative Research Proposal 
 
















Talia Z. Nadel 
Certificate: Social Determinants of Health 
Department of Sociomedical Sciences, Mailman School of Public Health 








 Despite being a relatively common autoimmune disease that physicians are trained to 
recognize, the average time to diagnosis for patients with systemic lupus erythematosus (SLE) is 
approximately 6 years. In addition to this troubling overall diagnostic delay, women typically 
wait almost two years longer than men to receive a diagnosis, and there is also emerging 
preliminary evidence of racial/ethnic disparities in time to diagnosis. Approximately 90% of SLE 
patients are women, and the prevalence of SLE is higher among racial and ethnic minorities than 
among white people in the United States. Despite this, the literature regarding the factors that 
contribute to diagnostic delay is not robust, and there is a significant gap when it comes to 
examining gender and racial disparities in particular. The proposed study will utilize qualitative 
research methods informed by narrative inquiry and grounded theory to examine the diagnostic 
journeys of women with systemic lupus erythematosus in New York City with a focus on the 
ways in which gender and race shape patient-provider interactions and time to diagnosis. Data 
collection will occur in two phases. The first phase will involve conducting 20 key informant 
interviews with medical providers, social service providers, and employees at patient advocacy 
organizations as well as observing patient support group sessions. The second phase will consist 
of semi-structured in-depth interviews with 12 women with SLE. Drawing from a narrative 
approach, each woman will be interviewed three separate times. These diagnostic journey 
narratives will be analyzed using thematic analysis. 
 
Statement of the Problem 
Systemic lupus erythematosus (SLE) is a chronic, oftentimes debilitating autoimmune 
disease that can affect any organ in the body (Pascoe et al., 2017). The most commonly-
experienced symptoms are fatigue, joint pain, muscle pain, and skin and mucous membrane 
lesions, but without proper intervention and treatment, organ damage such as kidney failure can 
occur (Wallace & Gladman, 2019). The average time between the onset of symptoms and 
receiving a diagnosis is approximately 6 years (Lupus Foundation of America, 2019; Morgan et 
al., 2018). Women typically wait almost two years longer than men to receive a diagnosis, and 
while it remains understudied, evidence also points to potential racial/ethnic disparities 
(González et al., 2013; Morgan et al., 2018). While SLE is a complex illness with a wide array of 
potential symptoms and presentations, it is a relatively common autoimmune disease that all 
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physicians are trained to recognize and that rheumatologists are well-equipped to identify and 
treat. In addition, unlike other conditions with non-specific functional symptoms such as 
fibromyalgia, chronic pain, and myalgic encephalomyelitis, SLE has standardized diagnostic 
criteria that include laboratory tests (Wallace & Gladman, 2019). This suggests something else 
may be influencing time-to-diagnosis, but the literature regarding the factors that contribute to 
diagnostic delay is not robust, and there is a significant gap when it comes to examining gender 
and racial disparities in particular. Approximately 90% of SLE patients are women, and the 
prevalence of SLE is higher among racial and ethnic minorities than among white people (Pons-
Estel et al., 2010). Research shows that physicians are less likely to believe physical complaints 
and pain ratings from women and racial/ethnic minorities, which leads to their complaints often 
being dismissed. Previous studies of similar conditions found that women presenting at 
physicians’ offices with non-specific symptoms like pain and fatigue face gender-specific 
barriers to diagnosis. These barriers include providers believing women are exaggerating or 
inventing symptoms, dismissing their concerns, and suggesting their symptoms are psychological 
rather than physical (Swartz, 2018; Werner & Malterud, 2003). Additionally, sexism in patient-
provider relationships is racialized, as examinations of maternal morbidity and mortality have 
illuminated (De Marco et al., 2008). The purpose of this study is to examine the diagnostic 
journeys of women with systemic lupus erythematosus in New York City with a focus on the 
ways in which gender and race shape patient-provider interactions and time to diagnosis. 
 
Background and Significance  
Background 
Systemic lupus erythematosus (hereafter referred to as SLE or lupus) is estimated to affect 
between 300,000 and 2 million people in the United States, making it the second- or third-most 
common rheumatic autoimmune disorder (Wallace, 2008, p. 11). Prevalence estimates vary 
widely but tend to fall between 20 and 150 cases per 100,000 people, though this differs by 
race/ethnicity, gender, and country of residence (Schur & Hahn, 2019). While the mechanism for 
racial disparities in incidence and prevalence of SLE is unknown, it does not appear to be related 
to genetics or geographic ancestry. For example, SLE is quite rare in Africa, but people of 
African descent in the United States and Europe are significantly more likely than white people 
to be diagnosed (Pons-Estel et al., 2010, pp. 258–259). In Manhattan, the estimated age-
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standardized prevalence (per 100,000) is 64.3 for non-Hispanic white women, 91.2 for non-
Hispanic Asian women, 138.3 for Hispanic women, and 210.9 for non-Hispanic Black women 
(Izmirly et al., 2017, p. 2009). While the gender gap in time to diagnosis is more well-
documented, studies examining racial disparities in the overall time to diagnosis have been 
mixed, with Black women in one study in the UK reporting a shorter diagnostic delay than white 
women but no current evidence of similar patterns in the US (Morgan et al., 2018). However, 
there is data from the US demonstrating that women of color in general, and Black women in 
particular, have accumulated more organ damage and have more severe symptoms at the time of 
diagnosis, suggesting the potential of a greater delay (González et al., 2013). One factor 
contributing to this appears to be an increased wait time in receiving a specialist referral; African 
American, Hispanic, and Asian women with lupus are all significantly more likely than white 
women to wait longer than three months for a referral (Gaynon et al., 2018). This is likely a 
result of racism in the medical system. Racial discrimination in patient-provider interactions is 
well documented across a variety of health conditions and may have an impact on women of 
color’s ability to have providers take their symptoms seriously enough to warrant further action 
(Smedley et al., 2003). 
SLE is frequently difficult to diagnose because it is a complex illness with a wide variety of 
presentations that often mimic the symptoms of other conditions (Oglesby et al., 2014). 
Estimates of patients receiving a misdiagnosis of another condition prior to being correctly 
diagnosed with SLE range from approximately 50-75% (Kent et al., 2017, p. 1097; Morgan et 
al., 2018, p. 682; Sloan, Harwood, et al., 2020, p. 3). There is no one definitive test for the 
disease. Instead, clinicians draw from a combination of laboratory tests, exam findings (i.e. 
physical signs), and symptoms to determine if a patient meets the criteria for SLE (Hatfield-
Timajchy, 2008, p. 113). There are three major sets of criteria for diagnosis: the American 
College of Rheumatology criteria (ACR 1997), the Systemic Lupus International Collaborating 
Clinics criteria (SLICC 2012), and the European League Against Rheumatism / American 
College of Rheumatology criteria (EULAR/ACR 2019) (Aringer et al., 2020, p. 17). The 1997 
ACR criteria are by far the most commonly used (with some physicians using them in 
combination with the 2012 SLICC criteria), and the 2019 EULAR/ACR are so new that it is not 
known how they are being used in practice (Wallace & Gladman, 2019). All three sets of criteria 
were developed using primarily white patients in academic settings, which is a significant 
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limitation (Aringer et al., 2019; Wallace & Gladman, 2019). With the 1997 ACR criteria, a 
patient simply needs to meet any four out of the eleven possible criteria, while to differing 
degrees, both the 2012 SLICC and 2019 EULAR/ACR criteria use a weighted scoring system 
(Aringer et al., 2020). The 1997 ACR criteria are reproduced below in Table 1.  
 
Table 1: American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus 
Erythematosus (SLE) 1 
A person can be diagnosed with SLE if four of the eleven criteria are present at any time:  
Skin criteria  
1. Butterfly or “malar” rash (lupus rash over the cheeks and nose)  
2. Discoid rash (a thick, disk-like rash that scars, usually on sun-exposed areas)  
3. Sun sensitivity (rash after being exposed to ultraviolet A and B light)  
4. Oral ulcerations (recurrent sores in the mouth or nose)  
Systemic criteria  
5. Arthritis (inflammation of two peripheral joints with tenderness, swelling, or fluid)  
6. Serositis (inflammation of the lining of the lung (or pleuritis) or the heart (pericarditis))  
7. Kidney disorder (protein in urine samples or abnormal sediment in urine seen under a microscope)  
8. Neurologic disorder (seizures or psychosis with no other explanation)  
Laboratory criteria  
       9.    Blood abnormalities (hemolytic anemia, low white blood cell counts, low platelet counts)  
      10.   Immunologic disorder (blood testing indicating either a positive LE cell2 preparation, anti-dsDNA3,  
              false-positive syphilis test4 or positive anti-Sm5)  
      11.   Positive ANA6 blood test  
 
1 Table and footnotes reproduced from Table 3.1 (p.114) in Hatfield-Timajchy, K. S. (2008). Delayed diagnosis: The experience of women with 
systemic lupus erythematosus in Atlanta, Georgia (2008-99130-448; Issues 1-A). Emory University. 
2 Specific cell found in blood specimens of most lupus patients. 
3 Antibody and double-stranded DNA (Anti-dsDNA): Antibodies to DNA; seen in half of those with systemic lupus and implies serious disease. 
4 False-positive serologic test for syphilis: A blood test revealing an antibody that may be found in patients with syphilis and that gives false-
positive results in 15 percent of patients with SLE; associated with the lupus anticoagulant and antiphospholipid antibodies.  
5 Anti-Smith (anti-Sm) antibody; this type of antibody is found only in lupus patients. 
6 Antinuclear antibodies (ANA): Proteins in the blood that react with the nuclei of cells. Seen in 96 percent of those with SLE, in 5 percent of 
healthy individuals, and in most patients with autoimmune diseases.  
 
Symptoms of note that are not included in the ACR criteria but are present in either the 
SLICC or EULAR/ACR criteria include fever, non-scarring alopecia, expanded neurologic 
symptoms, and lupus nephritis (as opposed to only generalized kidney disorder) (Aringer et al., 
2020). While fatigue is not included in any of the three sets of criteria, 80-100% of SLE patients 
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experience fatigue and patients frequently mention it as one of the most significant inhibitors of 
their quality of life (Pettersson et al., 2010; Wallace & Gladman, 2019). Similarly, muscle pain 
(as opposed to joint pain from arthritis, which is included) is another frequent, debilitating 
symptom that is not detailed within any of the diagnostic criteria (Sloan, Harwood, et al., 2020; 
Sutanto et al., 2013). It is likely that these two symptoms, while extremely common, are not in 
the official diagnostic criteria because they are more subjective and non-specific. However, these 
are also the symptoms that most commonly prompt a patient to first seek medical care, so it is 
crucial for doctors to be aware of their role in the presentation of SLE (Hatfield-Timajchy, 2008, 
p. 20). Patients frequently see their primary care provider or a dermatologist before realizing 
their symptoms are manifestations of a larger, multi-system condition and being referred to a 
rheumatologist and/or nephrologist for treatment (Hatfield-Timajchy, 2008, p. 123). 
For the purposes of this study, the term “diagnostic journey” will refer to the experience of 
attempting to obtain a diagnosis starting from the onset of symptoms. Some qualitative studies of 
SLE include the diagnostic journey as part of their focus, but very few studies focus exclusively 
on this period and its significance. Patient-provider interactions across the entire illness course 
for SLE have, however, been examined more frequently using qualitative methodologies 
(Sutanto et al., 2013). Because of the non-specific nature of many of SLE’s symptoms and the 
fact that it is characterized by flare-ups and periods of remission, patients often have difficulty 
communicating their symptoms to their doctors, which strains patient-provider relationships 
(Hatfield-Timajchy, 2008; Sloan, Naughton, et al., 2020). Another factor contributing to difficult 
patient-provider interactions is the frequently-reported disparity between patient and provider 
priorities. Patients often want more care and treatment for their quality of life symptoms, while 
providers are more focused on observable findings such as laboratory tests, joint damage, and 
organ damage (Sloan, Naughton, et al., 2020, p. 4).  
Currently, there are four published studies focusing specifically on patients’ perspectives of 
their diagnostic journeys, two of which are journal articles and two of which are doctoral 
dissertations (Hatfield-Timajchy, 2008; McNeil, 2018; Mendelson, 2009; Price & Walker, 2014). 
Hatfield-Timajchy’s (2008) dissertation was a mixed-methods medical anthropology study that 
examined diagnostic journeys and the impact of diagnostic delays for African American and 
white women in Atlanta using interviews, participant observation, and surveys. Half of her 
participants experienced a diagnostic delay of four or more years, and she identified limited 
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access to specialists as a major structural barrier (Hatfield-Timajchy, 2008, p. 126). In addition to 
struggling to get a referral or find an in-network specialist, participants sometimes saw multiple 
specialists at a time who focused on separate organ systems and frequently disagreed with each 
other and failed to piece together the patient’s systemic illness (Hatfield-Timajchy, 2008, pp. 
126–127). One of the factors that contributed to participants’ frustration with being disbelieved 
by their providers was the transience of their symptoms. Their appointments would not always 
line up with a disease flare, and they struggled to have their symptoms taken seriously when they 
could not be directly observed (Hatfield-Timajchy, 2008, p. 128). McNeil’s (2018) dissertation 
utilized a phenomenological approach to look specifically at the diagnostic journeys of women 
of color throughout the US. Her participants struggled with ambiguity throughout the diagnostic 
journey and sought the validation of an official diagnosis (McNeil, 2018, p. 146). Once they 
received a diagnosis, though, they framed the journey as something extremely difficult that they 
“pushed through” and felt they came out stronger on the other side of it (McNeil, 2018, p. 156). 
Mendelson (2009) explicitly examined the gendered nature of the diagnostic journey in her 
feminist analysis of written narratives submitted by women with lupus recruited from online 
support communities. She theorizes the diagnosis journey as a liminal state, and many of her 
participants struggled with their symptoms being dismissed or misattributed to mental health 
conditions before they received the correct diagnosis (Mendelson, 2009, p. 397). One of the 
major themes that arose was women being told that what they were experiencing was “all in 
[their] head” and the ways in which this negatively impacted their sense of self (Mendelson, 
2009, p. 398). Price and Walker (2014) utilized a variety of qualitative methods including focus 
groups, artistic representations, and narrative interviews to explore the diagnostic journey as a 
state of “vertigo” characterized by uncertainty and insecurity. For their participants, receiving a 
diagnosis was often not a discrete moment but rather an ongoing, distressing process (Price & 
Walker, 2014, p. 229). They argue that physicians dealt with their own uncertainty during a 
difficult diagnostic process by falling back on explanations of mental health (Price & Walker, 
2014, p. 230). While many of the women used the internet to research their symptoms and gain 
clarity about their condition, they still faced an uphill battle when trying to convince their 
providers to consider an SLE diagnosis, and this often further strained the patient-provider 





Gaining an understanding of women’s diagnostic journeys is particularly important because 
of the negative health outcomes and psychological consequences that arise from diagnostic 
delays. The longer it takes to receive a diagnosis of SLE and initiate treatment, the more likely it 
is that organ damage will occur or worsen (Sebastiani et al., 2016). At all levels of disease 
severity, patients diagnosed within six months of symptom onset have less frequent flares, lower 
all-cause and SLE-related healthcare utilization, and lower healthcare costs compared to those 
who wait at least six months to receive a diagnosis (Oglesby et al., 2014).  The presence of social 
support is linked to improved health outcomes in people with chronic illnesses, but social 
support can wane during a protracted journey to diagnosis as friends and family begin to doubt 
the veracity of a person’s experience when it is continually not validated by medical 
professionals (Brennan & Creaven, 2016; Meghani & Green, 2018; Sloan, Naughton, et al., 
2020). In the context of endometriosis, which is similarly characterized by years-long diagnostic 
delays, Ballard et al. (2006, p. 1299) found that receiving a diagnosis “sanction[ed] access to 
social support” and legitimized women’s inability to perform work and social duties because 
women could finally “prove” that what they were experiencing was medical in nature. It is 
reasonable to assume that a similar process may be occurring for women with SLE. 
In a recent series of studies, Melanie Sloan and colleagues identified a number of 
mechanisms through which the experience of having a protracted journey to diagnosis negatively 
impacts SLE patients’ interactions with the healthcare system even after they receive a diagnosis 
(Sloan, Harwood, et al., 2020; Sloan, Naughton, et al., 2020). Participants’ interactions with 
providers during the diagnostic journey shaped how they approached their medical relationships 
going forward and frequently led to an ongoing lack of trust, even when seeing new or different 
providers (Sloan, Naughton, et al., 2020, p. 3).  Approximately half of their participants initially 
received a misdiagnosis of either a mental health problem (including “health anxiety” and 
hypochondria) or medically unexplained symptoms before being correctly diagnosed with SLE 
(Sloan, Harwood, et al., 2020, p. 3). “Medically unexplained symptoms” (MUS) is a broad 
category describing subjective symptoms (e.g. fatigue, pain) that cannot be traced to any 
underlying pathology or clear cause and encompasses conditions such as fibromyalgia and 
chronic pain (Samulowitz et al., 2018). Sloan, Naughton, et al. (2020, p. 4) found that these 
mental health and MUS misdiagnoses frequently led to self-doubt and insecurity, particularly 
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when a participant’s family members sided with the provider. After being diagnosed, some 
patients continue to underreport their mental health and cognitive symptoms even though these 
symptoms are well documented in SLE because they fear their providers will then misattribute 
their physical symptoms to mental illness (Sloan, Naughton, et al., 2020, p. 6). This 
complements prior research that patients frequently underreport disease flares, and, importantly, 
that physicians are typically unaware of this phenomenon (Kent et al., 2017). In addition to 
underreporting symptoms, Sloan, Naughton, et al. (2020, p. 5) also found that patients often 
avoid seeking care altogether as a result of previous negative experiences with providers, 
particularly those that occurred during the diagnostic journey. Given these long-lasting impacts, 
uncovering the complexities of the diagnostic journey, including the ways in which gender and 
race shape women’s experiences, will have an impact above and beyond shortening the 
diagnostic delay itself.  
 
Theoretical Lens  
 The proposed study will be grounded in feminist theory with a specific emphasis on 
intersectional feminism and feminist approaches to diagnostic uncertainty and chronic illness. 
Developed by feminist legal scholar Kimberlé Crenshaw in her seminal 1991 article, 
intersectionality provides a framework to describe the ways in which individual social identity 
categories like race, gender, socioeconomic status, and sexual orientation intersect at the 
individual or micro level to reflect larger, interlocking sociostructural systems of privilege and 
oppression such as sexism, racism, and classism (Bowleg, 2012, p. 1267; Crenshaw, 1991). 
Crucially, this theory posits that experiences of privilege and oppression are not additive (e.g. 
straight white women experience only sexism, queer white women experience sexism + 
heterosexism, and straight Black women experience sexism + racism) but are rather mutually 
constitutive (Bowleg, 2012, p. 1271). This theory helps illuminate the ways in which the type of 
sexism experienced by women is influenced by their race, and the type of racism experienced by 
women is influenced by their gender. Because SLE is a disease that affects almost exclusively 
women, and because the prevalence is higher among women of color than in white women, 
intersectionality will provide an important framework for understanding the ways in which 
micro-level patient-provider interactions during the diagnostic journey are reflective of macro-
level interlocking sociostructural forces like racism and sexism.  
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 Because women are disproportionately affected by conditions with non-specific 
symptoms like pain and fatigue and because studies have consistently shown that men and 
women receive disparate treatment for these conditions, there is a growing body of feminist 
theoretical literature focusing on the role of sexism and gender norms in the treatment of women 
with chronic illnesses. In a review of the literature on gender bias in healthcare, Samulowitz et 
al. (2018, p. 9) found that women receive less pain medication, including opiates, compared to 
men and also are more likely to be given antidepressants and mental health referrals rather than 
pain relief. Drawing a through line from nineteenth-century conceptualizations of hysteria, 
feminist scholars emphasize dismissive and incredulous attitudes by providers who tell women 
that they are exaggerating, imagining, or overreacting to their symptoms and/or that their 
symptoms are a physical expression of psychological distress (Samulowitz et al., 2018; Swartz, 
2018; Werner et al., 2004). Because of the subconscious, entrenched nature of sexism, these 
experiences are not limited to male providers, although in some studies the provider’s gender has 
been found to impact interactions and treatment (Samulowitz et al., 2018, p. 9). It is also 
important to note here that, in addition to the aforementioned gender disparities, there is a robust 
literature on racial disparities in pain management. Black people in the United States, who are at 
an increased risk of SLE, are disproportionately more likely to have their pain both 
underestimated and undertreated (Meghani & Green, 2018, p. 827). 
The majority of these frameworks have been developed for conditions such as 
fibromyalgia and chronic pain that don’t have standardized diagnostic tests or criteria. However, 
based on the few available studies that explore this phenomenon, women with SLE seem to face 
the same gendered obstacles as women with MUS throughout their diagnostic journeys 
(Hatfield-Timajchy, 2008; McNeil, 2018; Mendelson, 2009). Currently, Mendelson (2009) is the 
only scholar who has both focused explicitly on the diagnostic journey and done so through the 
lens of gender. She found that prior to diagnosis, women were frequently told their symptoms 
were simply a result of stress and depression, and that they were sometimes offered 
antidepressants rather than pain medication (Mendelson, 2009). While this study examined the 
role of gender, it did not also examine race, and all of the participants were recruited from online 
support groups, limiting analytic generalizability. This leaves plenty of unexplored territory for 
the proposed study, which can also serve to strengthen her conclusions. Swartz’s (2018) 
“feminist bioethics approach to diagnostic uncertainty” will be particularly applicable for the 
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proposed study. In providing a framework for the experiences of women with contested illnesses, 
she highlights the role of providers as gatekeepers or experts, the vulnerable and subordinate 
position of female patients attempting to obtain answers and care, and the ways in which societal 
“views about the credibility of women and the seriousness of their complaints” permeate the 
diagnostic process (Swartz, 2018, p. 38). Another relevant theory for the proposed study is 
Malterud's (1999) “gendered construction of diagnosis.” Arguing from a semiotic constructivist 
perspective, she emphasizes the role of social and cultural context in medical interpretation and 
views the diagnostic process as one of “perception, interpretation, narration, and negotiation” 




Specific Aims  
1. Elicit provider and patient advocate perspectives on women’s diagnostic journeys and the 
factors that may contribute to protracted diagnostic journeys. 
2. Explore women’s journeys from symptom onset to obtaining a diagnosis of systemic 
lupus erythematosus. 
a. Examine women’s experiences interacting with medical and social service 
providers throughout their diagnostic journeys. 
b. Explore women’s experiences with implicit and explicit sexism and racism on 




Overview of Study Design and Approach 
The proposed study will achieve the above aims by utilizing qualitative research methods 
informed by narrative inquiry and grounded theory.  Qualitative methods are best suited for this 
study because of the limited preliminary research on diagnostic journeys for women with SLE, 
particularly when it comes to experiences of implicit and explicit racism and sexism. Using 
qualitative methods will allow previously unexplored or underexplored key concepts and themes 
to emerge through semi-structured interviews and periods of observation. The study will be 
carried out in two phases, described below. 
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Phase I: In order to gain a better understanding of the salient issues and concepts and facilitate 
triangulation, the first phase will involve conducting key informant interviews with medical 
providers, social service providers, and employees at patient advocacy organizations as well as 
observing patient support group sessions. Speaking with medical providers will elucidate their 
own struggles to make a timely diagnosis of this complex illness as well as their perceptions of 
what patients are experiencing during the process. People with SLE frequently have difficulty 
working, may receive disability benefits, and/or may generally be in need of social services, and 
social workers will have intimate insights into the challenges their clients face (Schudrich et al., 
2012). Similarly, patient advocates will be familiar with patients’ most pressing concerns and be 
able to provide insight into which issues and experiences are most common. During support 
groups, patients will build off of each other’s comments, make connections, and perhaps feel 
more comfortable sharing difficult experiences because they will be in a space with others who 
understand their struggles.  
 
Phase II: Using an interview guide informed by the preliminary findings of Phase I, Phase II will 
consist of semi-structured in-depth interviews with women with SLE. Drawing from a narrative 
approach, each woman will be interviewed three separate times to elicit a complex and 
comprehensive account of her diagnostic journey. Utilizing multiple interviews will allow the 
interviewer to build trust and rapport with the participant and understand the intimate details of 
their diagnostic journey. The interviews will focus on the diagnostic journey as a whole and 
emphasize the nature and role of interactions with providers. A narrative approach is well-suited 
to an exploration of diagnostic journeys, which are a bounded period that begins with the onset 
of symptoms and “ends” with obtaining a diagnosis. Additionally, narrative inquiry emphasizes 
“sensemaking,” which is the process by which people make sense of their lived experiences 
within their social and structural contexts (Ntinda, 2019, p. 411). Because diagnostic journeys 
are often characterized by prolonged periods of uncertainty, using a narrative approach will help 
elucidate how participants grappled with and understood this uncertainty throughout the various 






Sampling and Recruitment  
Phase I: There will be 20 key informant interviews: 5 with patient advocates, 5 with social 
service providers, 5 with primary care providers (physicians and/or nurse practitioners), and 5 
with specialists (rheumatologists as well as nephrologists and/or dermatologists). 
Rheumatologists will be located through the Manhattan Lupus Surveillance Program’s registry 
of hospitals, private rheumatology practices, and specialty clinics (e.g. NYU Langone’s Lupus 
Center) that serve patients with SLE (Izmirly et al., 2017). Using online searches, a selection of 
private and health system-affiliated (e.g. Mount Sinai, New York Presbyterian) nephrology, 
dermatology, and primary care practices from a variety of neighborhoods in New York City will 
be identified and contacted. Patient advocates and social service providers will be located and 
contacted via online searches for relevant organizations and agencies within New York City such 
as the Lupus Foundation of America’s northeast regional chapter. Connections to support groups 
for observation will be made through patient advocates with a goal of observing at least two 
support group sessions.    
 
Phase II: The sample of SLE patients will be 12 women ages 25-60 in New York City who have 
received a diagnosis of systemic lupus erythematosus within the past year. This will facilitate 
detailed accounts of participants’ diagnosis journeys as they will have been “completed” quite 
recently. This recency will also allow participants to focus in on the diagnostic journey itself, 
with less emphasis on their potential difficulties obtaining adequate treatment once they did get a 
diagnosis. Selecting a relatively small sample size for the in-depth interviews, with each 
participant being interviewed multiple times, is characteristic of narrative inquiry (Sharp et al., 
2019). The interviewer and participant will build rapport over the course of the interviews, and 
interviewing fewer people multiple times (as opposed to more people only one time) will allow 
for an exploration of the diagnostic journeys in all of their detail and complexity. In addition, the 
comprehensive first phase of the study, with key informant interviews from multiple perspectives 
and observation of support groups, will allow for triangulation of the data from these narratives. 
This study’s age range was selected to be within approximately one standard deviation of the 
mean age at diagnosis for women of all races in Manhattan. Nationally, most diagnoses occur 
between the ages of 37 and 50 for white women and between the ages of 15 and 44 for Black 
women (Schur & Hahn, 2019). In Manhattan specifically, Izmirly et al. (2017, p. 2011) found 
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that from 2007-2009, the mean±SD age at diagnosis was 40.1±16.6 for women, 42.2±17.7 for 
non-Hispanic whites, 39.2±16.3 for non-Hispanic Blacks, 39.6±17.0 for Hispanics, and 
37.9±16.0 for Asians.  
Women will be recruited via flyer/ads from a variety of sources within New York City to 
facilitate obtaining a sample with a variety of perspectives. These include support groups, lupus 
specialty clinics, rheumatology, dermatology, and nephrology practices, primary care practices, 
and online forums such as Facebook groups and message boards (e.g. LupusConnect). The four 
existing studies that focus specifically on the diagnostic journeys of women with SLE (described 
in detail above) all recruited primarily from in-person and/or online support groups (Hatfield-
Timajchy, 2008; McNeil, 2018; Mendelson, 2009; Price & Walker, 2014). Women who had less 
arduous diagnostic journeys, or who perhaps feel adequately supported by friends and family, 
would be less likely to seek out these groups (Price & Walker, 2014, p. 228). Including non-
support-group settings in the sampling frame will ensure that these women will also have an 
opportunity to tell their stories, as it is important to have an understanding of what factors 
positively impact women during the diagnostic journey. Women will first be recruited 
purposively based on race/ethnicity. In qualitative research, this type of sampling is used to 
ensure that the people in the sample will be able to provide relevant information based on a 
study’s specific questions and goals (Maxwell, 2012, p. 97). Race/ethnicity was selected as a 
criterion because one of the goals of this study is to elucidate women’s experiences of implicit 
and explicit racism during the diagnostic journey (see Aim 2b). Even though women of color are 
more likely to be diagnosed with SLE than white women, many studies still have samples that 
are primarily white and are therefore unable to adequately explore experiences of implicit and 
explicit racism in the medical system. Following purposive sampling, as themes begin to emerge 
during the iterative data analysis process, we will draw from grounded theory and employ 
theoretical sampling to refine concepts and fill in any gaps (Charmaz, 2007, pp. 11–12).  
 
Data Collection Methods 
Phase I: The principal investigator and a research assistant trained in qualitative interviewing 
will each conduct key informant interviews. These interviews will be face-to-face and last 
approximately 60 minutes. During the interviews, interviewers will make brief notes and then 
write up a full memo directly following the interview. Memos will include key points, what did 
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and did not go well during the interview, and proposed alterations to the interview guide. The 
interviews will be semi-structured, with interview guides modified to include questions based on 
the specific expertise of the key informant. Questions tailored to the different types of key 
informants will include:  
• Patient Advocates and Social Service Providers  
o What major challenges do your clients face when attempting to obtain a 
diagnosis? 
o What types of support systems (e.g. government assistance, online and in-person 
support group communities) are available to your clients? 
 How does this change before and after they receive an official diagnosis? 
o How does SLE impact your clients’ quality of life during the diagnostic journey? 
After they receive a diagnosis? 
• Primary Care Providers 
o What sort of symptoms make you suspect the patient may have SLE? 
o What typically leads you to refer the patient to a specialist and/or order testing? 
o What factors might lead you to believe that what the patient is experiencing is 
actually the result of stress and/or mental health issues? 
o Describe an example of a patient where you were skeptical about the presence or 
severity of their symptoms and/or whether or not they truly had lupus. 
• Specialists 
o Which set(s) of diagnostic criteria do you use? 
o How do you translate what a patient is saying about their lived experience (e.g. 
mentions being more tired than usual) into symptoms? 
o How do you decide to run tests? 
o Describe an example of a patient where you were skeptical about the presence or 
severity of their symptoms and/or whether or not they truly had lupus. 
o What frustrates you most about the diagnostic process? 
o What makes for a successful patient-provider relationship? 
For support group observations, the principal investigator will solely be observing the 
session and will not ask support group members specific questions. As described in detail under 
“Protection of Human Subjects and Data Management,” support group participants will be made 
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aware that a researcher is coming to observe their session and will consent to observation. 
During the support group, the researcher will write brief notes (e.g. key quotes, major concepts). 
Immediately following the observation, the researcher will write up detailed field notes and make 
note of any specific topics they want to follow up on during the in-depth interviews. 
 
Phase II: In-depth interviews will be conducted by the principal investigator. All interviews will 
be face-to-face. Each of the twelve participants will be interviewed three times, with 
approximately one month between interviews and interviews lasting on average between 60 and 
90 minutes. The interviews will be semi-structured, with an interview guide that is informed by 
the key informant interviews and observed support group sessions from Phase I. Over the course 
of the three interviews, the goal will be to build trust with the participant and elicit a detailed, 
comprehensive account of their diagnostic journey. It may be that the participant will not feel 
comfortable sharing some of the most difficult or distressing aspects of this journey until the 
second or third interview. For example, participants may want to establish themselves as reliable 
and/or build credibility with the interviewer before sharing how a provider attributed their 
symptoms to mental illness or said what they were experiencing was “all in their head,” which 
participants in previous studies frequently experienced (Mendelson, 2009). All interviews will be 
tape-recorded and transcribed. As with the key informant interviews, the interviewer will jot 
down brief notes during the interview and then write up a memo following the interview. The 
consent process, including procedures for making participants feel safe and comfortable, is 
described in detail below under “Protection of Human Subjects and Data Management.”  
 The first interview will aim to elicit more of a basic chronology of the diagnostic journey 
so that subsequent conversations can delve further into how participants felt during each phase of 
the journey, what factors were important in shaping their experience, etc. (Creswell & Poth, 
2016, p. 69). Questions establishing this basic chronology will include: 
• When did you first start experiencing symptoms of SLE? 
• What initially made you seek out care? 
• How long was the gap between the onset of symptoms and seeking care? 
• How did you decide that what you were experiencing warranted medical attention? 
• What was the trajectory of seeing various providers and obtaining referrals up until you 
received your diagnosis? 
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o (E.g. “I first saw my primary care provider, who referred me to a dermatologist 
for my rash, who referred me to a rheumatologist who ultimately diagnosed me”) 
• How many total providers did you see?  
o What were their specialties? 
• How did you describe your symptoms to providers? 
• Once you sought medical care, how long did it take to receive an official diagnosis? 
• What sort of diagnostic tests and/or physical exams were performed? 
• How was the diagnosis ultimately made? 
After establishing this basic outline of the diagnostic journey, subsequent conversations will 
focus in on topics such as patient-provider interactions and social support. There will be a semi-
structured interview guide with questions to cover during the second and third interview, and the 
interviewer will have leeway to jump around the guide and probe based on what direction the 
conversation goes in and what the participant brings up. Questions during this phase of 
interviews will include: 
• How was your ability to work and engage in social activities impacted throughout the 
diagnostic journey? 
• What was the response of your friends and family when you first started experiencing 
symptoms? What about when you initially sought care? 
• How did friends and family support you during periods of uncertainty? 
• Did friends and family ever question or discount your experience?  
• How did levels of support from your loved ones change over the course of the diagnostic 
journey?  
• During periods of uncertainty, what impact did the lack of a diagnosis from your medical 
provider have on levels of support from your loved ones?  
o Probes: Were they angry on your behalf? Did they accept what the providers said 
and agree that nothing was medically wrong? 
• How did providers respond to you when you explained your symptoms? 
• What was your relationship like with your various providers? 
• How did your providers support you? What could they have done to better support you? 
• What were some of the most difficult parts of the experience? 
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• What made things harder? 
• What made things easier? 
• Who did you go to for support (e.g. friends, family, support groups, online communities)? 
• How did you feel when you received your diagnosis? 
 
Data Analysis Plan and Methods 
All interview transcripts will be uploaded to Dedoose for analysis. Themes and concepts 
that emerge from the memos written following key informant interviews and support group 
observations will inform the creation of the in-depth interview guide. Diagnostic journey 
narratives will be analyzed using thematic (rather than structural or discourse) analysis as the 
goal will be to identify common themes, salient concepts, turning points, and areas for further 
exploration (Creswell & Poth, 2016, p. 200). Data analysis of the in-depth interview transcripts 
will be an iterative process that is concurrent with data collection to facilitate theoretical 
sampling. As themes begin to emerge, additional participants will be identified based on 
concepts that need to be clarified and/or require different perspectives (Rapley, 2016).  
To develop the codebook, the principal investigator and the research assistant will each 
read the same three transcripts, which will be selected based on their conceptual diversity (i.e. 
with the goal that they will together incorporate a wide variety of the relevant themes and 
concepts). The researchers will immerse themselves in the data by closely reading the transcripts 
and making margin notes (Rapley, 2016). Next, they will come up with a preliminary list of 
codes. These will include a combination of a priori codes (generated through theoretical and 
background literature as well as the key informant interviews and interview guide) and codes that 
emerge from the data. The researchers will meet to compare their lists and create the codebook. 
Next, they will begin individually applying the codebook to transcripts. Protocols for 
maintaining validity and reliability during the data analysis process, including ensuring that each 
member of the team is consistently and reliably applying the codebook, are discussed in detail 
below. Codes will be applied to short segments of text (rather than line-by-line), and more than 
one code may be applied to a given segment (i.e. double-coding). These overlaps will facilitate 
the identification of emerging themes. Throughout the coding process, the researchers will write 
memos in Dedoose whenever thoughts, questions, emerging themes, or suggested alterations to 
the codebook come up. After all of the transcripts are coded, the researchers will then create a 
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matrix-style data display to group the codes into themes and identify representative quotes from 
the transcripts. The data display will also allow for comparisons of experiences across axes of 
difference, such as race and time to diagnosis. The analytic tools within Dedoose, memos written 
during the analysis process, and frequent team meetings will all facilitate this process. 
 
Validity and Reliability 
 The research team will employ a number of different safeguards to maintain validity and 
reliability. It should first be noted that unlike quantitative research, which seeks a representative 
sample that will allow for statistical generalizability, in qualitative research the goal is analytic 
generalizability. Despite the small, non-random sample, the employment of purposive and then 
theoretical sampling (facilitated by an iterative data analysis process) will ensure a 
representativeness of concepts and themes relevant to this specific research question and allow 
for an analysis of the consistency of these themes (Corbin & Strauss, 1990, p. 421). The two-
phase structure and multiple methods of data collection (i.e. observation, key informant 
interviews, and in-depth interviews) will also facilitate data triangulation. Conducting key 
informant interviews with stakeholders from multiple perspectives and observing support group 
sessions will inform and contextualize the subsequent in-depth interviews. It will also allow for 
the interrogation of discrepancies between the key informant and patient perspectives. During the 
data collection process for the in-depth interviews, the interviewer will pay close attention to 
how a participant’s narrative may change over the course of multiple interviews (Lewis, 2014). 
This will include probing to elicit more information or clarifications, especially in cases where 
there are gaps in participants’ narratives or they contradict themselves. In addition, we will pay 
close attention to any “negative cases,” (i.e. participants whose experiences do not fit into and/or 
directly go against emerging themes) in the in-depth interviews. These may support our findings 
if participants deliberately position themselves as “exceptions to the rule,” or they may require us 
to re-evaluate or amend our findings (Rapley, 2016). Regardless, they will help us strengthen the 
validity of our findings. 
 Prior to conducting data analysis, researchers will write subjectivity memos. These will 
include a discussion of how their personal lived experiences, including the identities they hold 
and any prior training and experiences, may impact their interpretation of the data. In particular, 
the researchers will think critically about their own experiences with chronic illness and/or the 
 
 20 
medical system. After laying out their potential biases in the subjectivity memos, the researchers 
will make plans for deliberately attending to this bias throughout the analysis process. This will 
include making use of the “memos” feature in Dedoose to make notes throughout the coding 
process whenever they have a strong emotional reaction to an interview (surprise, sadness, 
connections to personal experiences, etc.) or have trouble understanding what a respondent is 
trying to communicate. To maintain reliability, two members of the research team (the principal 
investigator and the research assistant) will use the codebook to separately code a subsection of 
the same transcript. They will then calculate an inter-coder agreement (ICA) as the number of 
agreements divided by the total number of agreements and disagreements. Next, they will 
discuss and resolve disagreements by going code by code, talking through their thought 
processes, and referring back to the codebook. After resolving all disagreements that can be 
resolved, they will re-calculate the ICA and also make any needed changes to the codebook. The 
codebook will be continually refined as new concepts and themes emerge, and previously coded 
transcripts will be re-examined to apply these new codes, if applicable.  
 
Protection of Human Subjects and Data Management 
 Prior to data collection, all research materials, including interview guides, recruitment 
flyers, and consent forms, will be reviewed and approved by the Columbia University 
Institutional Review Board. Support group facilitators will notify members that a researcher will 
be coming to observe the next session. They will explain the general purpose of the study as well 
as the processes in place for keeping information confidential and de-identified. This way, 
support group participants who do not want to be observed will know in advance and can choose 
not to attend that session. Consent and confidentiality information will then be repeated at the 
beginning of the session being observed. Research participants for the key informant interviews 
and in-depth interviews will all be given randomly assigned numbers (e.g. KIP01 for a key 
informant interview with a patient advocate), and transcripts and memos will only be identified 
with this number and the date of the interview. Signed IRB-approved consent forms will be 
stored separately from transcripts and memos. Consent forms will be read aloud to participants, 
and they will have an opportunity to ask questions and clarify any points of confusion. The only 
identifying information collected will be participants’ gender, race, age, and years of experience 
(for key informants). During the consent process, interviewers will explain to participants that 
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their names will not be used in connection with the data, and that all information will be kept 
confidential. For key informants, the consent process will also involve explaining that the 
information they provide will in no way be connected with or shared with their employers. All 
study information will be stored on encrypted, password-protected computers. Recordings and 
transcripts of interviews and support group sessions will only be shared with members of the 
research team for the purposes of data analysis. As noted above, we will use Dedoose for data 
analysis. Security settings within Dedoose will be configured so that only members of the 
research team will be granted permission to view and code transcripts.   
 Sharing their diagnostic journeys may be emotionally taxing for in-depth interview 
participants, and every effort will be made to create a safe, comfortable, and confidential space 
for them to share their stories. As discussed in more detail above, conducting multiple interviews 
with each participant will help build rapport and allow them to feel safe sharing difficult 
experiences. Interviewers will make it clear to participants that they can choose not to answer 
any question, and that they may end the interview or ask to have the recording stopped at any 
time. Additionally, resources will be made available to all participants following the interviews. 
These will include information about local and online support groups, resources regarding 
obtaining disability benefits and other social services, and referrals to local therapists who 
specialize in treating patients with chronic illnesses. Following key informant and in-depth 




 Diagnostic delays and their associated negative health consequences are well documented 
among SLE patients. Despite this, there are very few studies that focus specifically on how 
people with SLE experience and make sense of their protracted journeys to diagnosis. SLE 
almost exclusively affects women, and its prevalence is higher among people of color than white 
people. However, the studies that do exist fail to grapple with and adequately examine the impact 
of implicit and explicit sexism and racism during the diagnostic journey. The proposed study will 
fill an important gap in the literature by using feminist theory to explicitly frame the diagnostic 
journey as a gendered and racialized experience as well as utilizing qualitative methods to 
explore how women make sense of and are impacted by this experience. This study will also 
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have the benefit of examining this issue from multiple angles. It will utilize key informant 
interviews with a variety of stakeholders, including providers, as well as interviews and periods 
of observation with the patients themselves, which will elicit complex and robust accounts of 
their diagnostic journeys. Given that SLE is such a complex disease, there will invariably be 
periods of uncertainty while patients and providers work together to find the correct diagnosis. 
The proposed study will help elucidate the specific challenges women face during these 
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